Shots:

• PerkinElmer to acquire Oxford Immunotec for $22/ share with a premium of ~28.3% to the closing price/ share of $17.15 on Jan 5- 2021- making a total deal value $591M. The transaction is expected to be completed in H1’21
• The acquisition allows the PerkinElmer to strengthen its portfolio of advanced infectious disease testing solutions to include tuberculosis detection for better serving across the globe
• The deal will enable PerkinElmer to combine its channel expertise & workflow and testing capabilities with Oxford Immunotec’s proficiencies in T cell immunology with its test kits for latent tuberculosis

 ­ Ref: BusinessWire | Image: Oxford Immunotec